morningstar analyst damien conover thinks read will continue to integrate wyeth, the company pfizer bought for $68 billion, and look for others. >> i see that cost-cutting continuing to happen, utilizing some of wyeth's key pipeline products to augment pfizer's pipeline. and then also do the acquisitions like the recently announced king acquisition. we are weigh expecting one more acquisition of that size by 2012. pfizer shares rallied on the new c.e.o.'s first day, up 0.5%. over the past year, though, pfizer stock has lost 9%. and that's tonight's "market focus." >> tom: an $8 billion a year business runs the risk of shutting down next year. it's a shutdown with ripple effects both on and off the field. tonight's "beyond the scoreboard," our look at the business of sports, begins with contract talks between the n.f.l. and its players union. rick horrow is a sports business analyst and c.e.o. of horrow sports ventures. welcome back. we're talking about the nfl and collective bargaining agreement due to expire march of 2011. just a few months away. a few weeks after super bowl. how is the l